ClinicalTrials.gg
CompletedNCT01992159Updated Mar 25, 2019Results posted

Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

A Phase 2 interventional study of Romosozumab and Placebo in Postmenopausal Osteoporosis (PMO), sponsored by Amgen. Completed at 27 sites in Japan. Open to female participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-25.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2012, registered Nov 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
7th of 12
252 · median 268
Started
2012
with 2 others
Phase 2
3 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
9 of 12
Amgen

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 7th largest by enrollment, is one of 3 that started in 2012, is one of 3 in phase 2, and was the 5th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment with romosozumab increases bone mineral density in Japanese women with postmenopausal osteoporosis.

03

Conditions studied

  • Postmenopausal Osteoporosis (PMO)

Keywords

  • Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ambulatory, Japanese women with osteoporosis (defined as bone mineral density T-score of ≤ -4.00 at the lumbar spine or BMD T-score of ≤ -3.50 at the total hip, or femoral neck)

Exclusion criteria

Exclusion Criteria:

  • Severe osteoporosis
  • Use of agents affecting bone metabolism
  • History of metabolic or bone disease (except osteoporosis)
  • Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)
  • Current hyper- or hypocalcemia
  • Current, uncontrolled hyper- or hypothyroidism
  • Current, uncontrolled hyper- or hypoparathyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.

    Drug: Placebo

  • Experimental
    Romosozumab 70 mg

    Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.

    Drug: Romosozumab

  • Experimental
    Romosozumab 140 mg

    Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.

    Drug: Romosozumab

  • Experimental
    Romosozumab 210 mg

    Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.

    Drug: Romosozumab

Interventions

  • Administered by subcutaneous injection

    Also known as: AMG 785, EVENITY™

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine

    Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine

    Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

    Time frame: Baseline and 6 months

  2. Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip

    Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

    Time frame: Baseline and 6 months

  3. Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip

    Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

    Time frame: Baseline and 12 months

  4. Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck

    Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

    Time frame: Baseline and 6 months

  5. Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck

    Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

    Time frame: Baseline and 12 months

  6. Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)

    Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12

  7. Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)

    Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12

  8. Percent Change From Baseline in Osteocalcin

    Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12

  9. Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)

    Time frame: Baseline, week 1, and months 1, 2, 3, 6, 9, and 12

  10. Area Under the Curve Through Month 12 of P1NP

    Time frame: Baseline, week 1 and months 1, 2, 3, 6, 9, and 12.

07

Results

Posted Mar 25, 2019

Participant flow

This study was conducted at 24 centers in Japan. The first participant was enrolled on 12 October 2012 and the last participant enrolled on 15 October 2013.

Participant flow — Overall Study
MilestonePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Started63636363
Received treatment63636363
Completed first 12 months of study59566359
Completed59556259
Not completed4814
Withdrew: Withdrawal by subject4703
Withdrew: Adverse event0101
Withdrew: Death0010

Outcome measures

PrimaryPercent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine

Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine0.9 (0.1 to 1.8)8.4 (7.6 to 9.3)13.3 (12.1 to 14.5)16.9 (15.5 to 18.4)
Statistical analysis
  • Placebo vs Romosozumab 70 mg · Repeated Measures Model · p = < 0.0001 (P-values were adjusted for multiplicity using a combination of a sequential test procedure and Hochberg's method to control type 1 error for the primary endpoint.) · Treatment difference: 7.5
  • Placebo vs Romosozumab 140 mg · Repeated Measures Model · p = < 0.0001 (P-values were adjusted for multiplicity using a combination of a sequential test procedure and Hochberg's method to control type 1 error for the primary endpoint.) · Treatment difference: 12.4
  • Placebo vs Romosozumab 210 mg · Repeated Measures Model · p = < 0.0001 (One-sided p-values were adjusted for multiplicity using a combination of a sequential test procedure and Hochberg's method to control type 1 error for the primary endpoint.) · Treatment difference: 16.0
SecondaryPercent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine

Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

Time frame:
Baseline and 6 months
Reported as:
Least squares mean · percent change
Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine1.2 (0.5 to 1.9)6.5 (5.7 to 7.2)10.2 (9.2 to 11.2)13.1 (11.7 to 14.5)
Statistical analysis
  • Placebo vs Romosozumab 70 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 5.3
  • Placebo vs Romosozumab 140 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 9.0
  • Placebo vs Romosozumab 210 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 11.9
SecondaryPercent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip

Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

Time frame:
Baseline and 6 months
Reported as:
Least squares mean · percent change
Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip0.6 (-0.0 to 1.3)1.2 (0.5 to 2.0)2.3 (1.7 to 2.9)3.2 (2.5 to 3.9)
Statistical analysis
  • Placebo vs Romosozumab 70 mg · Repeated Measures Model · p = 0.1250 · Treatment difference: 0.6
  • Placebo vs Romosozumab 140 mg · Repeated Measures Model · p = 0.0002 · Treatment difference: 1.7
  • Placebo vs Romosozumab 210 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 2.6
SecondaryPercent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip

Bone density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip0.6 (-0.0 to 1.3)2.1 (1.4 to 2.8)3.2 (2.6 to 3.9)4.7 (4.0 to 5.5)
Statistical analysis
  • Placebo vs Romosozumab 70 mg · Repeated Measures Model · p = 0.0012 · Treatment difference: 1.5
  • Placebo vs Romosozumab 140 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 2.6
  • Placebo vs Romosozumab 210 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 4.1
SecondaryPercent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck

Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

Time frame:
Baseline and 6 months
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck0.6 (-0.1 to 1.4)1.0 (0.1 to 1.8)1.9 (1.0 to 2.9)3.3 (2.1 to 4.4)
Statistical analysis
  • Placebo vs Romosozumab 70 mg · Repeated Measures Model · p = 0.2846 · Treatment difference: 0.3
  • Placebo vs Romosozumab 140 mg · Repeated Measures Model · p = 0.0151 · Treatment difference: 1.3
  • Placebo vs Romosozumab 210 mg · Repeated Measures Model · p = 0.0001 · Treatment difference: 2.6
SecondaryPercent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck

Bone mineral density was measured using dual-energy X-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging reader.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · percent change
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck0.3 (-0.6 to 1.2)1.9 (1.0 to 2.7)2.9 (2.1 to 3.8)3.8 (2.7 to 4.9)
Statistical analysis
  • Placebo vs Romosozumab 70 mg · Repeated Measures Model · p = 0.0067 · Treatment difference: 1.6
  • Placebo vs Romosozumab 140 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 2.6
  • Placebo vs Romosozumab 210 mg · Repeated Measures Model · p = < 0.0001 · Treatment difference: 3.5
SecondaryPercent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)
Time frame:
Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Reported as:
Mean · percent change
Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 1-2.5 ± 9.043.4 ± 24.065.9 ± 25.781.5 ± 34.6
Month 1-5.7 ± 22.132.2 ± 22.979.8 ± 41.7101.6 ± 41.1
Month 2-10.9 ± 18.5-0.7 ± 18.434.6 ± 38.259.8 ± 40.5
Month 3-11.5 ± 20.3-13.1 ± 18.314.9 ± 32.225.5 ± 33.4
Month 6-8.9 ± 23.3-16.8 ± 26.0-2.7 ± 28.02.4 ± 24.8
Month 9-2.1 ± 32.0-16.9 ± 31.3-9.1 ± 30.9-4.0 ± 31.5
Month 124.6 ± 37.9-11.1 ± 29.8-16.2 ± 27.4-13.1 ± 28.1
SecondaryPercent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)
Time frame:
Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Reported as:
Mean · percent change
Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 111.9 ± 27.8-28.0 ± 25.8-32.1 ± 32.8-42.0 ± 25.4
Month 114.9 ± 40.2-18.0 ± 34.3-8.0 ± 53.9-24.6 ± 30.5
Month 214.1 ± 41.6-2.3 ± 48.414.9 ± 67.80.1 ± 49.1
Month 316.1 ± 49.0-5.5 ± 48.328.9 ± 84.18.1 ± 53.8
Month 613.6 ± 49.8-10.8 ± 52.23.2 ± 71.8-13.4 ± 40.6
Month 912.6 ± 56.6-13.2 ± 53.0-8.0 ± 55.7-15.3 ± 44.8
Month 1235.4 ± 81.7-4.1 ± 47.22.1 ± 73.5-10.5 ± 53.8
SecondaryPercent Change From Baseline in Osteocalcin
Time frame:
Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Reported as:
Mean · percent change
Percent Change From Baseline in Osteocalcin
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 12.6 ± 18.16.5 ± 12.67.9 ± 17.05.5 ± 14.5
Month 1-3.8 ± 12.726.5 ± 20.451.2 ± 31.966.4 ± 31.3
Month 2-7.0 ± 13.413.7 ± 15.139.3 ± 31.648.9 ± 31.6
Month 3-7.2 ± 16.84.9 ± 17.528.4 ± 29.727.5 ± 22.3
Month 6-10.3 ± 15.9-5.5 ± 18.810.6 ± 24.79.3 ± 19.2
Month 9-8.4 ± 18.2-6.8 ± 22.5-0.9 ± 24.0-1.3 ± 18.9
Month 12-6.8 ± 20.6-8.6 ± 21.8-9.4 ± 22.1-8.9 ± 17.9
SecondaryPercent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)
Time frame:
Baseline, week 1, and months 1, 2, 3, 6, 9, and 12
Reported as:
Mean · percent change
Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)
percent changePlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Week 11.6 ± 13.414.0 ± 14.517.0 ± 16.420.1 ± 17.9
Month 1-0.5 ± 22.123.0 ± 19.951.3 ± 27.666.2 ± 31.9
Month 2-7.8 ± 16.98.7 ± 20.831.8 ± 27.955.1 ± 31.0
Month 3-9.5 ± 16.3-2.8 ± 14.923.5 ± 26.539.6 ± 33.2
Month 6-6.6 ± 20.5-9.0 ± 19.03.1 ± 21.613.2 ± 26.8
Month 9-7.0 ± 20.5-10.7 ± 21.7-2.6 ± 25.33.5 ± 23.8
Month 12-6.3 ± 22.7-13.2 ± 19.9-13.7 ± 23.3-9.3 ± 21.4
SecondaryArea Under the Curve Through Month 12 of P1NP
Time frame:
Baseline, week 1 and months 1, 2, 3, 6, 9, and 12.
Reported as:
Least squares mean · ug*month/L
Area Under the Curve Through Month 12 of P1NP
ug*month/LPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Area Under the Curve Through Month 12 of P1NP554.5 (523.0 to 585.9)539.2 (506.4 to 572.0)638.5 (607.9 to 669.2)708.3 (676.6 to 740.0)
Statistical analysis
  • Placebo vs Romosozumab 70 mg · ANCOVA · p = 0.5084 · Treatment difference: -15.3 · 95% CI -60.8 to 30.2ANCOVA model with the AUC of P1NP at month 12 as the dependent variable, and baseline P1NP and treatment (categorical) as the independent variables.
  • Placebo vs Romosozumab 140 mg · ANCOVA · p = 0.0002 · Treatment difference: 84.1 · 95% CI 40.1 to 128.0ANCOVA model with the AUC of P1NP at month 12 as the dependent variable, and baseline P1NP and treatment (categorical) as the independent variables.
  • Placebo vs Romosozumab 210 mg · ANCOVA · p = < 0.0001 · Treatment difference: 153.8 · 95% CI 109.2 to 198.4ANCOVA model with the AUC of P1NP at months 12 as the dependent variable, and baseline P1NP and treatment (categorical) as the independent variables.

Adverse events

Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/63 (7.9%)20/63 (31.7%)
Romosozumab 70 mg—6/63 (9.5%)33/63 (52.4%)
Romosozumab 140 mg—3/63 (4.8%)29/63 (46%)
Romosozumab 210 mg—2/63 (3.2%)32/63 (50.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
Acute myocardial infarctionCardiac disorders0/630/631/630/63
Angina pectorisCardiac disorders1/630/630/630/63
Angina unstableCardiac disorders0/630/630/631/63
Atrioventricular block second degreeCardiac disorders0/631/630/630/63
Coronary artery stenosisCardiac disorders0/631/630/630/63
Ventricular extrasystolesCardiac disorders1/630/630/630/63
CataractEye disorders0/630/630/631/63
Vitreous haemorrhageEye disorders0/630/630/631/63
Large intestine polypGastrointestinal disorders0/630/631/630/63
CholelithiasisHepatobiliary disorders0/631/630/630/63
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mg
NasopharyngitisInfections and infestations8/6317/6317/6320/63
ContusionInjury, poisoning and procedural complications5/636/632/631/63
Back painMusculoskeletal and connective tissue disorders4/632/635/633/63
EczemaSkin and subcutaneous tissue disorders1/634/635/631/63
HypertensionVascular disorders2/631/635/631/63
Abdominal pain upperGastrointestinal disorders4/630/631/633/63
Dental cariesGastrointestinal disorders1/634/633/632/63
Upper respiratory tract infectionInfections and infestations2/631/634/630/63
Ligament sprainInjury, poisoning and procedural complications4/631/630/633/63
OsteoarthritisMusculoskeletal and connective tissue disorders1/630/632/634/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Mean67.8 ± 7.266.5 ± 6.368.4 ± 6.068.3 ± 5.967.7 ± 6.4
Age, Customized
Age, Customized(Participants)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
< 65 years2730181893
≥ 65 to < 75 years22223434112
≥ 75 years1411111147
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Female63636363252
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Asian63636363252
Lumbar Spine Bone Mineral Density (BMD) T-score
Lumbar Spine Bone Mineral Density (BMD) T-score(T-score)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Mean-2.69 ± 0.52-2.73 ± 0.57-2.65 ± 0.66-2.72 ± 0.42-2.70 ± 0.54
Total Hip BMD T-score
Total Hip BMD T-score(T-score)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Mean-2.00 ± 0.60-1.97 ± 0.57-1.85 ± 0.68-1.95 ± 0.65-1.94 ± 0.63
Femoral Neck BMD T-score
Femoral Neck BMD T-score(T-score)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Mean-2.31 ± 0.47-2.27 ± 0.53-2.28 ± 0.65-2.32 ± 0.59-2.29 ± 0.56
Serum Procollagen Type 1 N-telopeptide (P1NP)
Serum Procollagen Type 1 N-telopeptide (P1NP)(μg/L)PlaceboRomosozumab 70 mgRomosozumab 140 mgRomosozumab 210 mgTotal
Median52.4 (41.9 to 62.9)51.9 (40.5 to 59.8)47.6 (37.7 to 54.9)50.9 (38.0 to 59.1)50.5 (38.6 to 59.4)

3 further baseline measures are reported on the registry.

08

Study locations

27 sites
  • Research Site
    Anjyo-shi, Aichi 446-0063, Japan
  • Research Site
    Fukuoka-shi, Fukuoka 814-0165, Japan
  • Research Site
    Kitakyushu-shi, Fukuoka 800-0057, Japan
  • Research Site
    Yanagawa-shi, Fukuoka 832-0059, Japan
  • Research Site
    Mizunami-shi, Gifu 509-6134, Japan
  • Research Site
    Sapporo-shi, Hokkaido 063-0814, Japan
  • Research Site
    Sapporo-shi, Hokkaido 065-0024, Japan
  • Research Site
    Morioka-shi, Iwate 020-0066, Japan
  • Research Site
    Yokohama-shi, Kanagawa 223-0062, Japan
  • Research Site
    Yokohama-shi, Kanagawa 231-0861, Japan
  • Research Site
    Kyoto-shi, Kyoto 602-8026, Japan
  • Research Site
    Sendai-shi, Miyagi 981-3132, Japan
  • Research Site
    Sendai-shi, Miyagi 983-0862, Japan
  • Research Site
    Saito-shi, Miyazaki 881-0113, Japan
  • Research Site
    Matsumoto-shi, Nagano 390-1401, Japan
  • Research Site
    Ueda-shi, Nagano 386-0151, Japan
  • Research Site
    Ueda-shi, Nagano 386-0405, Japan
  • Research Site
    Osaka-shi, Osaka 559-0011, Japan
  • Research Site
    Takatsuki-shi, Osaka 569-1123, Japan
  • Research Site
    Kita-adachi-gun, Saitama 362-0806, Japan
  • Research Site
    Hachioji-shi, Tokyo 192-0046, Japan
  • Research Site
    Kiyose-shi, Tokyo 204-0021, Japan
  • Research Site
    Minato-ku, Tokyo 108-0075, Japan
  • Research Site
    Ota-ku, Tokyo 146-0094, Japan
  • Research Site
    Shinagawa-ku, Tokyo 140-0011, Japan
  • Research Site
    Suginami-ku, Tokyo 166-0003, Japan
  • Research Site
    Toshima-ku, Tokyo 171-0033, Japan
09

References and documents

Publications

  • Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study. Bone. 2017 Oct;103:209-215. doi: 10.1016/j.bone.2017.07.005. Epub 2017 Jul 5. PubMed 28687496 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in Oct 2014, 23 months.

Results were first posted in Mar 2019, 4 years 5 months after primary completion. A results delay was requested in Sep 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2013
First posted
Nov 25, 2013
StartActual
Oct 12, 2012
Primary completionActual
Oct 9, 2014
CompletionActual
Jun 17, 2015
Results delay requested
Sep 11, 2015
Results first posted
Mar 25, 2019
Last update
Mar 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01992159
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
Oct 12, 2012
Primary completion
Oct 9, 2014
Completion
Jun 17, 2015
Results posted
Mar 25, 2019
Last update
Mar 25, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion